The DOI matches its Crossref record; 174 of the 174 references it cites were found in a registry or an index.
Suicidality and Risk of Suicide—Definition, Drug Safety Concerns, and a Necessary Target for Drug Development: A Consensus Statement
Abstract
OBJECTIVE: To address issues concerning potential treatment-emergent "suicidality," a consensus conference was convened March 23-24, 2009. PARTICIPANTS: This gathering of participants from academia, government, and industry brought together experts in suicide prevention, clinical trial design, psychometrics, pharmacoepidemiology, and genetics, as well as research psychiatrists involved in studies of major depression, bipolar disorder, schizophrenia, substance abuse/dependence, and other psychiatric disorders associated with elevated suicide risk across the life cycle. The process involved reviews of the relevant literature, and a series of 6 breakout sessions focused on specific questions of interest. EVIDENCE: Each of the participants at the meeting received references relevant to the formal presentations (as well as the slides for the presentations) for their review prior to the meeting. In addition, the assessment instruments of suicidal ideation/behavior were reviewed in relationship to standard measures of validity, reliability, and clinical utility, and these findings were discussed at length in relevant breakout groups, in the final plenary session, and in the preparation of the article. Consensus and dissenting views were noted. CONSENSUS PROCESS: Discussion and questions followed each formal presentation during the plenary sessions. Approximately 6 questions per breakout group were prepared in advance by members of the Steering Committee and each breakout group chair. Consensus in the breakout groups was achieved by nominal group process. Consensus recommendations and any dissent were reviewed for each breakout group at the final plenary session. All plenary sessions were recorded and transcribed by a court stenographer. Following the transcript, with input by each of the authors, the final paper went through 14 drafts. The output of the meeting was organized into this scholarly article, which has been developed by the authors with feedback from all participants at the meeting and represents a consensus view. Any areas of disagreement have been noted. CONCLUSIONS: The term suicidality is not as clinically useful as more specific terminology (ideation, behavior, attempts, and suicide). Most participants applauded the FDA's effort to promote standard definitions and definable expectations for investigators and industry sponsors by endorsing the terminology in the Columbia Classification Algorithm of Suicide Assessment (C-CASA). Further research of available assessment instruments is needed to verify their utility, reliability, and validity in identifying suicide-associated treatment-emergent adverse effects and/or a signal of efficacy in suicide prevention trials. The FDA needs to build upon its new authority to systematically monitor postmarketing events by encouraging the development of a validated instrument for postmarketing surveillance of suicidal ideation, behavior, and risk within informative large health care-related databases in the United States and abroad. Over time, the FDA, industry, and clinical researchers should evaluate the impact of the current Agency requirement that all CNS clinical drug trials must include a C-CASA-compatible screening instrument for assessing and documenting the occurrence of treatment-emergent suicidal ideation and behavior. Finally, patients at high risk for suicide can safely be included in clinical trials, if proper precautions are followed, and they need to be included to enable premarket assessments of the risks and benefits of medications related to suicidal ideation, suicidal behavior, and suicide in such patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As reviewed by Meyer et al. (27), these criteria are considered essential for judging the utility of scales assessing suicide-related phenomena”
From The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults (2011) · cites this paper as [27]
In the citing paper
“and the scale is unique among rating instruments in meeting all of these criteria.”
From The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults (2011) · cites this paper as [27]
In the citing paper
“This period of success was followed by a series of challenges, including a growing awareness of the long-term adverse effects of medications and of the inadequacy of long-term drug surveillance.”
From Pediatric psychopharmacology: Too much or too little? (2013) · cites this paper as [55]
In the citing paper
“Part of the issue was the failure to distinguish between suicidality and actual self-harm, but everyone involved in this issue agreed that current post-marketing surveillance of drugs is inadequate (55).”
From Pediatric psychopharmacology: Too much or too little? (2013) · cites this paper as [55]
Citations
Cites
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
Self-citationMessick, S. (1995) · American Psychologist · doi:10.1037/0003-066x.50.9.741 · Cited by 4,198
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Self-citationYatham, L., & Malhi, G. (2011) · Oxford University Press eBooks · doi:10.1093/med/9780199562305.001.0001 · Cited by 3,506
Assessment of suicidal intention: The Scale for Suicide Ideation.
Beck, A. T., Kovacs, M., & Weissman, A. (1979) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.47.2.343 · Cited by 3,419
Users' guides to the medical literature
Guyatt, G. H. (1993) · JAMA · doi:10.1001/jama.270.17.2096 · Cited by 2,970
Suicide as an outcome for mental disorders: A meta-analysis
Harris, E. C., & Barraclough, B. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.170.3.205 · Cited by 2,589
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
Rothwell, P. M. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17670-8 · Cited by 2,544
Herbst, A. L., Ulfelder, H., & Poskanzer, D. C. (1971) · New England Journal of Medicine · doi:10.1056/nejm197104222841604 · Cited by 2,520
Psychological autopsy studies of suicide: a systematic review.
CAVANAGH, J. T. O., CARSON, A. J., SHARPE, M., & LAWRIE, S. M. (2003) · Psychological Medicine · doi:10.1017/s0033291702006943 · Cited by 2,207
Cited by
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
“(27), these criteria are considered essential for judging the utility of scales assessing suicide-related phenomena, and the scale is unique among rating instruments in meeting all of these criteria.”
BackgroundSelf-citationNicotine receptors and depression: revisiting and revising the cholinergic hypothesis
Mineur, Y. S., & Picciotto, M. R. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.09.004 · Cited by 279
Severity and Variability of Depression Symptoms Predicting Suicide Attempt in High-Risk Individuals
Melhem, N. M., Porta, G., Oquendo, M. A., Zelazny, J., Keilp, J. G., Iyengar, S., Burke, A., Birmaher, B., Stanley, B., Mann, J. J., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.4513 · Cited by 246
“The median (range) time from the last assessment point to suicide attempt was 45 (1-126) weeks (30 [4-126] weeks for actual attempt).”
BackgroundSelf-citationIs it valid to measure suicidal ideation by depression rating scales?
Desseilles, M., Perroud, N., Guillaume, S., Jaussent, I., Genty, C., Malafosse, A., & Courtet, P. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.11.013 · Cited by 208
Systematic Review of Suicide in Autism Spectrum Disorder: Current Trends and Implications
Hedley, D., & Uljarević, M. (2018) · Current Developmental Disorders Reports · doi:10.1007/s40474-018-0133-6 · Cited by 176
Metadata
- Authors
- Meyer, R. E., Salzman, C., Youngstrom, E. A., Clayton, P. J., Goodwin, F. K., Mann, J. J., Alphs, L. D., Broich, K., Goodman, W. K., Greden, J. F., Meltzer, H. Y., Normand, S.-L. T., Posner, K., Shaffer, D., Oquendo, M. A., Stanley, B., Trivedi, M. H., Turecki, G., Beasley, C. M., Beautrais, A. L., Bridge, J. A., Brown, G. K., Revicki, D. A., Ryan, N. D., & Sheehan, D. V.
- Affiliations
- Harvard University (US)
- University of North Carolina at Chapel Hill (US)
- American Foundation for Suicide Prevention (US)
- George Washington University (US)
- Columbia University (US)
- Johnson & Johnson (United States) (US)
- Federal Institute for Drugs and Medical Devices (DE)
- Icahn School of Medicine at Mount Sinai (US)
- University of Michigan (US)
- Vanderbilt University (US)
- The University of Texas at Dallas (US)
- McGill University (CA)
- Eli Lilly (United States) (US)
- Yale University (US)
- Nationwide Children's Hospital (US)
- University of Pennsylvania (US)
- United BioSource Corporation (United Kingdom) (GB)
- University of Pittsburgh (US)
- University of South Florida (US)
- Corresponding author
- Meyer, Roger E.
- ORCID
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2010-08-15
- Volume
- 71
- Issue
- 08
- Pages
- e1-e21
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2074444215
- Cited by
- 129
- References
- 173
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 6 · 2023: 3 · 2022: 5 · 2021: 6 · 2020: 7 · 2019: 8 · 2018: 6 · 2017: 9 · 2016: 13 · 2015: 13 · 2014: 12 · 2013: 13 · 2012: 8
- FWCI
- 12.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- DigitalGeorgetown (Georgetown University Library) (submittedVersion)
- Funders
- National Institute of Mental Health (R01MH048514)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- suicidality, suicide risk, suicidal ideation, suicidal behavior, suicide attempts, suicide prevention, drug safety, adverse drug reactions, psychometric reliability and validity, post-marketing surveillance, FDA regulatory authority, psychiatric drug development, major depressive disorder, bipolar disorder, schizophrenia, substance use disorders
- MeSH terms
- Adolescent, Adult, Age Factors, Antidepressive Agents, Mental Disorders, Child, Clinical Trials as Topic, Consensus Statements as Topic, Major Depressive Disorder, Humans, Terminology as Topic, Psychometrics, Suicide, Suicide, Attempted, United States, United States Food and Drug Administration, Meta-Analysis as Topic, Reproducibility of Results, Randomized Controlled Trials as Topic, Risk Assessment, Drug Discovery, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Suicidality and Risk of Suicide—Definition, Drug Safety Concerns, and a Necessary Target for Drug Development: A Consensus Statement. https://app.cochat.ai/papers/10.4088/jcp.10cs06070blu
- The paper
- Meyer, R. E., Salzman, C., Youngstrom, E. A., Clayton, P. J., Goodwin, F. K., Mann, J. J., Alphs, L. D., Broich, K., Goodman, W. K., Greden, J. F., Meltzer, H. Y., Normand, S.-L. T., Posner, K., Shaffer, D., Oquendo, M. A., Stanley, B., Trivedi, M. H., Turecki, G., Beasley, C. M., . . . Sheehan, D. V. (2010). Suicidality and Risk of Suicide—Definition, Drug Safety Concerns, and a Necessary Target for Drug Development: A Consensus Statement. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.10cs06070blu
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.